[Clinical analysis of 20 patients with primary non-Hodgkin's lymphoma of nasal cavity and nasopharynx].
OBJECTIVE
To evaluate the treatment policy for non-Hodgkin's lymphoma of the nasal cavity and nasopharynx.


METHODS
Twenty patients with pathologically confirmed non-Hodgkin's lymphoma of nasal cavity and nasopharynx,treated from Jan. 2006 to Oct. 2010, were retrospectively reviewed.


RESULTS
The 3-year overall survival and complete response rates for all patients were 78% and 47% respectively. The 3-year overall survival rates for patients treated with chemotherapy and patients treated with chemotherapy plus radiotherapy were 75% and 82% respectively. The estimates of complete response for patients receiving chemotherapy alone and for patients receiving chemotherapy plus radiotherapy were 37% and 55%, respectively. The 3-year overall survival rates for patients who achieved complete response and patients who did not were 89% and 70%, respectively. The 3-year overall survival rates for patients in stage IE and stage II E were 92% and 57%, respectively.


CONCLUSIONS
There was no significant difference between chemotherapy alone and chemotherapy plus radiotherapy for the treatment of non-Hodgkin's lymphoma of the nasal cavity and nasopharynx. The 3-year overall survival rate for patients in stage IE was much higher than in stage II E. Early treatment is very important to improve the survival rate of the patients.
Department of Otolaryngology, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, 830054, China. abulajiang6462@sina.cn
Abulajiang
Department of Otolaryngology, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, 830054, China.
Youledusi
Department of Otolaryngology, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, 830054, China.
Xingzhi
X
Gu
D000328:Adult; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D009296:Nasal Cavity; D009303:Nasopharyngeal Neoplasms / Q000628:therapy; D009669:Nose Neoplasms / Q000628:therapy; D012189:Retrospective Studies; D015996:Survival Rate